ArticleNeoplasia (New York, N.Y.)2026

The benefit of deep genomic testing for asymptomatic high-risk individuals undergoing surveillance for pancreatic adenocarcinoma: European registry for hereditary pancreatic diseases (EUROPAC-PLUS).

Phillip J Hopley et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.